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ABSTRACT
Introduction: Streptococcus pneumoniae is the
leading cause of bacterial meningitis. Young
children, the elderly and those who are
immunocompromised or who suffer from
chronic diseases have the highest risk of
developing pneumococcal meningitis. A
7-valent pneumococcal conjugate vaccine
(PCV7) was licensed in 2000 in the US and in
2001 in Europe.
Methods: A literature search was performed in
PubMed to identify studies assessing the impact
of routine childhood PCV7 vaccination on
pneumococcal diseases. Here, we report the
impact on pneumococcal meningitis.
Results: A total of 17 articles reporting impact
data on pneumococcal meningitis were
included in this review: 11 from Western
Europe and 6 from North America. In the
post-vaccination period, compared with the
pre-vaccination period, a reduction ranging
from 59.2% in the US, 1 year after vaccine
introduction, to 100% in Belgium, 4 years after
vaccine introduction in vaccine-type (VT)
pneumococcal meningitis incidence was
reported in vaccine-eligible children in seven
studies. In addition, the majority of studies
reported reductions in VT and all-type
pneumococcal meningitis incidence in age
groups that were not vaccine-eligible.
Conclusions: The results from this review
demonstrate that PCV7 has had a significant
impact on pneumococcal meningitis across all
ages through its use in pediatric immunization
programs. With the introduction of 13-valent
PCV (PCV13) we can expect to see a reduction
in the incidence of pneumococcal meningitis
due to the six additional serotypes included,
as well as continued protection against
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pneumococcal meningitis due to PCV7
serotypes. Robust surveillance systems are
essential for the evaluation of the impact of
PCV13 on all-type pneumococcal meningitis
and for monitoring the evolution of
non-vaccine serotype pneumococcal meningitis.
Keywords: 7-Valent pneumococcal conjugate
vaccine; Direct vaccine impact; Indirect
vaccine impact; Pneumococcal meningitis;
Vaccine impact
INTRODUCTION
Streptococcus pneumoniae is the leading cause of
bacterial meningitis [1]. The risk of developing
pneumococcal meningitis is highest in young
children, the elderly and those who are
immunocompromised or who suffer from
chronic diseases [1]. In a global literature
review of children under 5 years of age, the
overall incidence rate of pneumococcal
meningitis was 17/100,000 (95% CI 8–21),
ranging from 6/100,000 (95% CI 5–9) in
Europe to 38/100,000 (95% CI 11–48) in Africa
[2]. In Europe, before the widespread use of
7-valent pneumococcal conjugate vaccine
(PCV7), the highest pneumococcal meningitis
rates were reported in children aged
\12 months in Spain (17.8/100,000) and in
children aged \2 years in Belgium (16.1/
100,000) [3]. Based on an extensive literature
review of publications from 1980 to 2005, the
overall case fatality rate (CFR) in children aged
\5 years with pneumococcal meningitis was
59% (95% CI 27–80%), ranging from 38% (95%
CI 32–58%) in Europe to 73% (95% CI 18–94%)
in Africa [2]. Mortality and morbidity rates in
patients with pneumococcal meningitis vary by
age, pneumococcal serotype and geographical
location [4, 5].
Untreated bacterial meningitis almost always
results in death, and even with optimal
treatment death and morbidity can occur [4].
Neurological sequelae are relatively common in
survivors of meningitis, particularly after
pneumococcal meningitis [4]. Sequelae, such
as hearing loss, blindness, seizures,
hydrocephalus, developmental delays and
motor deficits, have been reported in up to
20% of cases of pneumococcal meningitis in
Sweden and in 30% of cases in France, implying
a lifetime of considerable disability for those
who survive due to a preventable health burden
[3, 6]. In France, the mortality rate for bacterial
meningitis in the pre-vaccination period was
highest in very young children; 13.1%, 14.9%
and 9.9% for those aged \1 month, 1 to \2
months and 2 to \12 months, respectively,
compared with 6.3% in those aged C5 years [7].
Vaccines have playeda pivotal role in reducing
the burden of bacterial meningitis. Results from
clinical trials with the Haemophilus,
pneumococcal and meningococcal conjugate
vaccines clearly demonstrate their ability to
reduce the incidence of invasive disease,
including meningitis [8]. After the introduction
of the Haemophilus influenzae type b (Hib)
conjugate vaccine, there was a substantial
decrease in the incidence of Hib meningitis,
while the incidences of pneumococcal and
meningococcal meningitis remained stable [6].
PCV7 was initially licensed in the US in 2000
and in Europe in 2001; it was introduced into
national immunization programs (NIP) in 2000
in the US and in 2006–2008 in many EU
countries. It has been shown to have a dramatic
effect on vaccine-type invasive pneumococcal
disease (VT-IPD), including meningitis, in both
vaccination-target populations and also in older
children and adults via an indirect effect (herd
effect) [9]. The observed increase in non-VT-IPD
has not counter-balanced the decrease in VT-IPD,
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leading to an overall net reduction in all-type IPD
[9]. To address the increase in non-VT-IPD,
higher valency PCVs have been developed and
have replaced PCV7 in most national
immunization programs [10].
To obtain a baseline for the measurement
of the impact of the higher-valent PCVs
on pneumococcal meningitis, we have
summarized the data available on the impact
of PCV7 on the incidence of all-type and VT-
pneumococcal meningitis, in those targeted for
vaccination and in those not targeted for
vaccination (indirect effect) in North America
and Western Europe.
METHODS
The data presented here are part of a larger
global literature review on the impact of PCV7
on pneumococcal diseases. The search method
has been previously described [9]. In summary,
on 19 March 2011 we used the following terms
to search PubMed: (pneumonia OR ‘‘invasive
pneumococcal disease’’ OR IPD OR ‘‘otitis
media’’ OR death) AND [(pneumococcal AND
conjugate AND vaccin*) OR PCV]. In this paper,
we summarize the data from studies that
reported the results from the assessment of
the impact of PCV7 on all-type and
VT-pneumococcal meningitis in Western
Europe, and North America (no studies from
Australia were found) for all ages that were
published between January 2000 and March
2011. Before/after studies were included if the
impact data (percentage change in crude or
adjusted incidence rates) were provided or
could be calculated. The calculation used
was [(incidence pre-vaccination - incidence
post-vaccination)/incidence pre-vaccination] 9 100.
We excluded publications that reported
efficacy (i.e., randomized clinical trials),
modeling or health economics studies, studies
on specific populations (e.g., those with
comorbidities such as HIV-positive, patients
with sickle-cell disease) and studies for which
the denominator was unknown.
RESULTS
A total of 1,007 publications were identified
from the global search, and after two rounds of
screening 84 were selected for inclusion in the
global literature review (Fig. 1). The main
reasons for exclusion were: cohort study with
no comparative group (epidemiology data);
modeling or cost-effectiveness studies; only
specific patient subgroups; review articles and
no incidence data or insufficient data for
calculating incidence (mainly missing data for
the denominator). From these, 17 articles
reporting data on the impact of routine
childhood PCV vaccination on the incidence
of pneumococcal meningitis were analyzed: 6
from North America; 11 from Western Europe
(1 Austria, 1 Belgium, 1 Denmark, 1 France, 5
Spain, 1 The Netherlands, 1 England and Wales)
and none from Australia [1, 11–26]. The
characteristics of these studies are summarized
in Table 1. Three of the North American studies
used data from the Center for Disease Control
(CDC) Active Bacterial Core Surveillance (ABCs)
database [23–25]; they used the same pre-PCV
vaccination period (1998–1999) but analyzed
different post-PCV vaccination periods and
populations.
Data on the absolute number of cases were
not always available and when available
were provided in a variety of ways. For
example, overall in France there were 771
cases of pneumococcal meningitis in the
pre-vaccination period and 420 in the
post-vaccination period; in children aged
\2 years there were 181 and 74 cases,
respectively [19]. In the UK, in children aged
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\5 years, there were 107 cases of all-type
pneumococcal meningitis in the pre-vaccination
period and 49 in the post-vaccination period;
there were 82 and 4 cases of VT-pneumococcal
meningitis, respectively [21].
Impact on VT-Pneumococcal Meningitis
in Vaccine-Eligible Populations
The impact of PCV7 vaccination on
VT-pneumococcal meningitis in vaccine-eligible
populations ranged from -59.2% (US, in 2001,
1 year after vaccine introduction in the NIP)
to -100% (Belgium, 4 years after vaccine
introduction in the NIP), with a median of
-92.8% (Table 2) [12, 23]. In two other studies
in the US, comparing post-vaccination periods
of 2004–2005 and 2006–2007 with the same
pre-vaccination period as the US study
mentioned above, the impact was higher at
-92.8% and -97.4%, respectively [23–25].
Impact on All-Type Pneumococcal
Meningitis in Vaccine-Eligible Populations
The impact of PCV7 vaccination on all-type
pneumococcal meningitis in vaccine-eligible
populations ranged from -4.5% (in Spain, in
one hospital) to -100% (in another Spanish
study in the Basque Country and Navarre) with
a median of -47.7% (Table 3) [1, 11–14, 16, 19,
20, 25].
Impact on VT-Pneumococcal Meningitis
in Vaccine-Non-Eligible Populations
The impact of PCV7 vaccination
on VT-pneumococcal meningitis in
vaccine-non-eligible populations ranged from
?43.2% (in Spain in subjects aged C18 years, in
one hospital) to -87.5% (in US in subjects aged
C65 years), with a median of -67.1% (Table 4)
[15, 21, 24, 25].
Fig. 1 Summary of the results from literature search and screening
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Table 1 Summary of studies included in the review
Study ID (references)/
country (speciﬁc area)















National active hospital and laboratory
surveillance database





\2 years All-type; VT;
NVT; VRT2–5 years
\5 years
Hanquet et al. [12]/
Belgium
Laboratory surveillance data (62% of
hospitals)
PCV7 in NIP in 2004—
partially reimbursed; in Jan
2007 free for\2 years with
catch-up for 2 years/3 ? 1
2002–2003/
2007, 2008
\2 years All-type; VT;
NVT2–4 years
Harboe et al. [13]/
Denmark
National laboratory surveillance system PCV7 in NIP in 2007 with
2-dose catch-up for










Rodenburg et al. [14]/
Netherlands (25% of
population)
National Reference Laboratory PCV7 in 2006/3 ? 1 2004–2006/
2006–2008






Ardanuy et al. [15]/
Spain (one hospital in
southern Barcelona)
Single hospital, prospective study from
1997 to 2007
PCV7 introduced in 2001, but












Retrospective and prospective data from
nine hospitals
PCV7 introduced in 2001, but








Calbo et al. [17]/Spain
(two hospitals in one
health district in
Barcelona region)
Data from two hospitals PCV7 introduced in 2001, but




Guevara et al. [18]/
Spain (Navarre)
Active surveillance with participation of
all six laboratories in the region
PCV7 introduced in 2001, but





Lepoutre et al. [19]/
France (National)
Two active hospital-based laboratory-
based surveillance networks
PCV recommended for at-risk
children\2 years in 2003;
extended to all children
\2 years in June 2006/2 ? 1
2001–2002/
2006









Prospective study in one hospital PCV7 introduced in 2001, but
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Table 2 PCV7 impact on VT-pneumococcal meningitis in vaccine-targeted age groups






Hanquet et al. [12] (Belgium) 2002–2003 13.4 2008 0 -100.0
Lepoutre et al. [19] (France) 2001–2002 5.6 2006 1.0 -82.1
Hsu et al. [25] (US) 1998–1999 8.2 2004–2005 0.6 -92.8
Whitney et al. [23] (US) 1998–1999 10.3 2001 4.2 -59.2
2–4 years
Hsu et al. [25] (US) 1998–1999 0.9 2004–2005 0.1 -84.7
Hanquet et al. [12] (Belgium) 2002–2003 1.2 2008 0 -100.0
\5 years
Pilishvili et al. [24] (US) 1998–1999 3.8 2007 0.1 -97.4
Miller et al. [21] (England and Wales) 2000–2006 2.4 2009–2010 0.1 -95.1
Hennessy et al. [26] (US) 1995–2000 6.0 2001–2003 1.3 -78.3
% overall change data were taken from the original publications when available, any observed differences between these and


















Tsai et al. [1]/US
(National)










VT vaccine type, NVT non-vaccine type, VRT vaccine-related type, HPAHealth Protection Agency, CDC Center for Disease Control and Prevention, NIP
National Immunization Programme, PCV pneumococcal conjugate vaccine, NIS Nationwide inpatient sample
a ABCs (Active Bacterial Core Surveillance) is run by the CDC and covers a population of 29,757,552 persons in California (San Francisco County and
children\5 years in Alameda and Contra Costa counties); Colorado (ﬁve county Denver area); Connecticut; Georgia (20 county Atlanta area); Maryland
(six county Baltimore area); Minnesota; New Mexico; New York (15 county Rochester and Albany areas and children\5 years in Erie county); Oregon
(three county Portland area); Tennessee (20 counties)
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Impact on All-Type Pneumococcal
Meningitis in Other Age Groups
Many studies provided data on all-type
pneumococcal meningitis for different
age groups, including age groups that
could contain both vaccine-eligible and
non-vaccine-eligible subjects; these data have
been summarized in Table 5. The impact of
PCV7 vaccination on all-type pneumococcal
meningitis in these other age groups ranged
from ?137.0% (in Spain in subjects aged
C18 years, in one hospital) to -76.9% (in
another Spanish study in the Basque Country
and Navarre, in subjects aged\5 years) (Table 5)
[1, 11, 13, 15–22, 24, 25]. A range of 0% (in
France) to -37.5% (in the US), with a median of
-25.6%, was reported in five studies that
provided data for the impact on all-type
pneumococcal meningitis in all ages (Table 5).
Table 3 PCV7 impact on all-type pneumococcal meningitis in vaccine-targeted age groups






Hsu et al. [25] (US) 1998–1999 10.2 2004–2005 3.7 -64.0
Tsai et al. [1] (US) 1994–1999 7.7 2001–2004 2.6 -66.2
Aristegui et al. [16] (Spain) 1998–2001 12.8 2002–2003 4.3 -66.4
Rendi-Wagner et al. [11] (Austria) 2001–2004 6.0 2004–2006 2.9 -51.7
Harboe et al. [13] (Denmark) 2000–2007 13.2 2008 6.9 -47.7
Rodenburg et al. [14] (Netherlands) 2004–2006 14.7 2006–2008 9.6 -34.7
Hanquet et al. [12] (Belgium) 2002–2003 19.3 2008 13.1 -32.1
Lepoutre et al. [19] (France) 2001–2002 8.0 2006 6.0 -25.0
Munoz-Alamagro et al. [20] (Spain) 1997–2001 11.2 2002–2006 10.7 -4.5
2–4 years
Aristegui et al. [16] (2–5 years) (Spain) 1998–2001 4.5 2002–2003 0 -100.00
Hanquet et al. [12] (Belgium) 2002–2003 3.0 2008 1.1 -63.3
Munoz-Almagro et al. [20] (Spain) 1997–2001 4.5 2002–2006 2.3 -48.9
Harboe et al. [13] (Denmark) 2000–2007 0.7 2008 0.5 -28.6
Hsu et al. [25] (US) 1998–1999 1.0 2004–2005 0.9 -8.4
Tsai et al. [1] (US) 1994–1999 0.9 2001–2004 0.5 -44.4
% overall change data were taken from the original publications when available, any observed differences between these and
the apparent % overall change based on the incidence data in the table are due to rounding all incidence data to one decimal
place
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Evolution of Non-Vaccine-Type
Pneumococcal Meningitis in Vaccine-Eligible
and Non-Eligible Populations After PCV7
Introduction
Eight studies reported the evolution of
the incidence of non-vaccine-type
(NVT)-pneumococcal meningitis in different
age groups after PCV7 introduction [11, 12,
14, 15, 19, 21, 24, 25]. The incidence of
NVT-pneumococcal meningitis was low in the
pre-vaccination period, ranging from 0 in
children aged 2–4 years in the US to 5.8/100,000
in children aged\2 years in Belgium [12, 25]. In
vaccine-eligible populations, three studies
reported an increase of ?104.2% (from 2.4 to
4.9/100,000) in France, ?125.9% (from 5.8 to
13.1/100,000) in Belgium and ?272.7% (from
0.77 to 2.87/100,000) in the US, although the
absolute incidence remained low [12, 19, 25].
In children aged 5–17 years in one study in
the US, there was no change in the incidence
of NVT-pneumococcal meningitis, whereas,
overall, in all ages there was a significant
60% increase [25]. In vaccine-non-eligible
populations, all studies reported an increase
in the incidence of NVT-pneumococcal
meningitis, ranging from ?45% in those aged
5–54 years in the UK to ?215.9% (from 0.44 to
1.39/100,000) in all adults in Spain [15, 21].
In those aged C65 years, in the US, a decrease
of -36.7% (from 0.79 to 0.50/100,000) was
reported, whereas in another study in the US, an
increase of 27.3% (from 1.1 to 1.4/100,000) was
reported [24, 25]. In the UK, for this age group,
an increase of 20.0% (0.25–0.30/100,000) was
reported [21].
DISCUSSION
There was a substantial reduction in
VT-pneumococcal meningitis in both
vaccine-eligible and vaccine-non-eligible age
groups. While the rate reductions of
VT-pneumococcal meningitis were generally
similar between different age groups, the










Hsu et al. [25] (US) 5–17 years 1998–1999 0.10 2004–2005 0.09 -10.0
18–39 years 1998–1999 0.30 2004–2005 0.10 -66.7
40–64 years 1998–1999 0.62 2004–2005 0.24 -61.3
C65 years 1998–1999 0.82 2004–2005 0.27 -67.1
Pilishvili et al. [24] (US) 18–64 years 1998–1999 0.50 2007 0.10 -80.0
C65 years 1998–1999 0.80 2007 0.10 -87.5
Ardanuy et al. [15] (Spain) C18 years 1997–2001 0.37 2005–2007 0.53 ?43.2
Miller et al. [21] (England
and Wales)
5–64 years 2000–2006 0.10 2009–2010 0.03 -70.0
C65 years 2000–2006 0.18 2009–2010 0.05 -72.2
% overall change data were taken from the original publications when available, any observed differences between these and
the apparent % overall change based on the incidence data in the table are due to rounding all incidence data to one decimal
place
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Rendi-Wagner et al. [11] (Austria) 2001–2004 1.3 2004–2006 0.8 -38.5
\5 years
Pilishvili et al. [24] (US) 1998–1999 4.7 2007 1.7 -63.8
Aristegui 2007 [16] (Spain) 1998–2001 7.9 2002–2003 1.8 -76.9
Calbo et al. [17] (Spain) 1999–2001 3.4 2002–2004 1.4 -58.5
Guevara et al. [18] (Spain) 2001–2002 6.0 2006–2007 6.4 ?6.7
Miller et al. [21] (England
and Wales)
2000–2006 3.2 2009–2010 1.4 -54.7
Rendi-Wagner et al. [11] (Austria) 2001–2004 3.1 2004–2006 1.6 -48.4
\18 years
Hsu et al. [25] (US) 5–17 years 1998–1999 0.27 2004–2005 0.29 ?7.4
Tsai et al. [1] (US) 5–17 years 1994–1999 0.3 2001–2004 0.2 -33.3
Lepoutre et al. [19] (France) 2–15 years 2001–2002 0.5 2006 0.5 0
Harboe et al. [13] (Denmark) 5–17 years 2000–2007 0.2 2008 0.1 -50.0
Munoz-Alamagro et al. [20]
(Spain)
5–17 years 1997–2001 0.3 2002–2006 0.4 ?33.3
5–64 years
Guevara et al. [18] (Spain) 5–64 years 2001–2002 1.3 2006–2007 1.2 -7.7
Miller et al. [21] (England
and Wales)
5–64 years 2000–2006 0.2 2009–2010 0.2 0
Hsu et al. [25] (US) 18–39 years 1998–1999 0.6 2004–2005 0.4 -28.6
Hsu et al. [25] (US) 40–64 years 1998–1999 1.2 2004–2005 1.1 -3.3
Tsai et al. [1] (US) 18–64 years 1994–1999 0.8 2001–2004 0.7 -12.5
Harboe et al. [13] (Denmark) 18–49 years 2000–2007 0.7 2008 0.6 -14.3
Harboe et al. [13] (Denmark) 50–64 years 2000–2007 2.1 2008 1.3 -38.1
Lepoutre et al. [19] (France) 16–64 years 2001–2002 0.6 2006 0.6 0
C18 years
Albrich et al. [22] (US) 1999–2000 ND 2000–2004 ND -58.0a
Ardanuy et al. [15] (Spain) 1997–2001 0.8 2005–2007 1.9 ?137.5
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pre-PCV7 incidence in children aged \2 years
was much higher than in the other age groups
so that the relative reduction was greater for this
age group. The reduction in VT-pneumococcal
meningitis was partially offset by an increase in
NVT-pneumococcal meningitis, but generally
the increase was not sufficient to prevent an
overall reduction; the exceptions to this were
generally in the older age groups in studies that
were not national (Table 5) [13, 15, 18, 20].
Thus, PCV7 has reduced the incidence of
all-type pneumococcal meningitis across all
ages, which is a substantial public health benefit.
For the older age groups, the reduction in
VT-pneumococcal meningitis is possible
evidence of a herd effect. All but one of the
studies, in Denmark, reported a reduction in
those aged C65 years, ranging from 2.6 to 54.2
(Table 5). However, these data should be
interpreted with caution due to the low
incidence of VT and all-type pneumococcal
meningitis in these age groups. In addition,
there may be some protection through
23-valent pneumococcal polysaccharide
vaccine (PPV23) vaccination in the elderly and
adults with comorbidities. However, two
studies, one in the US (in adults, with and
without PPV23 indications) and one in the UK
(in those aged C65 years), reported that after
PPV23 introduction there was no evidence of a
decrease in the incidence of IPD (not just












Hsu et al. [25] (US) 1998–1999 1.9 2004–2005 0.9 -54.2
Tsai et al. [1] (US) C65 years 1994–1999 1.2 2001–2004 0.8 -33.3
Lepoutre et al. [19] (France) C65 years 2001–2002 1.4 2006 1.3 -7.1
Harboe et al. [13] (Denmark) C65 years 2000–2007 2.7 2008 3.0 ?11.1
Guevara et al. [18] (Spain) C65 years 2001–2002 3.9 2006–2007 3.8 -2.6
Miller et al. [21] (England and Wales) C65 years 2000–2006 0.4 2008–2010 0.3 -18.6
Overall study population
Hsu et al. [25] (US) 1998–1999 1.1 2004–2005 0.8 -30.1
Tsai et al. [1] (US) 1994–1999 0.8 2001–2004 0.5 -37.5
Harboe et al. [13] (Denmark) 2000–2007 1.6 2008 1.2 -25.6
Guevara et al. [18] (Spain) 2001–2002 2.0 2006–2007 1.9 -5.0
Lapoutre et al. [19] (France) 2001–2002 0.9 2006 0.9 0.0
% overall change data was taken from the original publications when available, any observed differences between these and
the apparent % overall change based on the incidence data in the table is due to rounding all incidence data to one decimal
place
a Only the % overall change was given
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vaccine; however, after the introduction of
PCV7 in the childhood vaccination
programmes, there was a reduction in the
incidence of IPD caused by the PCV7 serotypes
[27, 28].
Serotypes 19A and 7F have been reported to
be responsible for NVT-pneumococcal
meningitis in children after the introduction
of PCV7 in two recent studies in France and the
UK [29, 30]. In addition, in the UK, serotypes 1,
3, 22F and 33F were also found to be responsible
for NVT-pneumococcal meningitis [30].
The increased incidence of pneumococcal
meningitis caused by non-PCV7 serotypes
indicates the need for continued
epidemiological surveillance and the
development of vaccines with a broader range
of protection. The availability of higher valency
conjugate vaccines should contribute to the
continued reduction in the incidence of
pneumococcal meningitis. It was estimated
that, in children aged \5 years in the UK in
2009–2010, vaccine serotype coverage for
pneumococcal meningitis was 39% for
10-valent PCV (PCV10) and 65% for 13-valent
PCV (PCV13) [5]. For the 2004–2005 season in
the US, the vaccine serotype coverage was
27.4% for PCV10 and 50.0% for PCV13 [31].
Pneumococcal meningitis is a deadly disease,
with an estimated worldwide CFR in children
aged \5 years of 59%, compared with 5% for
pneumococcal pneumonia, based on an
extensive literature review from 1980 to 2005
[2]. The CFR varies in different regions of the
world, but even in Europe, for this period, the
CFR for pneumococcal meningitis in children
\5 years was estimated to be 38%, while in the
Americas it was estimated to be 48%. In the
studies included in this review, there were only
a few that provided meningitis-specific
mortality data or CFR; several provided data
for pneumococcal IPD-mortality rates [1, 11, 13,
18, 24, 26]. One of the studies in the US
reported that the mortality rates fluctuated
from 1994 to 1999, before the introduction of
PCV7, decreased sharply in 2000 and 2001 and
remained relatively stable in 2002–2004,
whereas the CFRs fluctuated over this period [1].
The incidences of pneumococcal meningitis,
both in the pre-vaccination and
post-vaccination eras, were variable between the
studies. This variability may be due to several
factors including under reporting, differences in
reporting methods, differences in blood-culture
practices and antibiotic prescribing [3]. This
emphasizes the need for well organized, robust,
surveillance systems to enable the impact of
vaccination on IPD, especially pneumococcal
meningitis, to be monitored [2, 3, 32].
The different time periods studied and
countries in which the studies were conducted
could contribute to the variability, since
circulating pneumococcal serotypes show
temporal and geographical variations [33–35].
In addition, the pre-vaccination and
post-vaccination periods studied, particularly
in relation to the date of PCV7 introduction,
can have a significant impact. There were also
differences in the introduction of PCV7 in terms
of catch-up campaigns, which has an effect on
the rapidity of impact. In the studies included
in this analysis, there were different vaccination
schedules (3 ? 1 and 2 ? 1) used with differing
rates of uptake; for example, in the UK, there
was rapid uptake after introduction into the NIP
with a 2 ? 1 schedule, whereas in Spain there
was slow uptake after introduction through the
private market with a 3 ? 1 schedule [18, 21,
36].
One limitation of our review is that in the
search strategy we used the term ‘invasive
pneumococcal disease’ and not ‘meningitis’
specifically: to assess the impact of this, we
retrospectively performed a search which
Adv Ther (2013) 30:748–762 759
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identified four publications, two from Northern
France (using the same data source but for
different periods) and two from Spain (one of
which was in Spanish) [37–40]. Data from a
national study in France has already been
included [19]. In addition, one other study
reporting data from 252 pediatric wards in
France could not be included as incidence data
were not available for the calculation of the
impact [29]. In this study, although the number
of cases of pneumococcal meningitis did not
decline between before PCV7 introduction
(2001–2002) and after (2007–2008), there was
a reduction in PCV7-type pneumococcal
meningitis from 65.7% to 17.7%. This
reduction was greatest in children aged
\2 years (from 70.1% to 10.1%). The number
of cases of NVT-pneumococcal meningitis
increased over this period, mainly 19A in
children aged \2 years (8.1–26.9%) and 7F in
older children (1.9–10%) [29].
CONCLUSION
PCV7 has had a significant impact on the
overall incidence of pneumococcal meningitis,
despite an increase in NVT-pneumococcal
meningitis. The higher valency vaccines
contain many of the serotypes that are now
more commonly responsible for pneumococcal
meningitis in both children and adults [5]. With
the introduction of PCV13 we can expect to see
a reduction in the incidence of pneumococcal
meningitis due to the additional six serotypes
included, as well as continued protection
against IPD due to PCV7 serotypes. Robust
surveillance systems will be essential for the
evaluation of the impact of PCV13 on all-type
pneumococcal meningitis and for monitoring
the evolution of NVT-pneumococcal
meningitis.
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